Clinical Trial Update: Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency [Phase 2, Phase 3]

View source ↗

Summary

This update indicates that cisplatin is being studied in patients with pancreatic adenocarcinoma who have homologous recombination deficiency, with Phase 2 and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)

Snippet

Sponsor: Fudan University | Conditions: Pancreatic Adenocarcinoma, Homologous Recombination Deficiency | Phase 2, Phase 3 | Status: RECRUITING